Biora Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	0	0.31	1.25	0.16	143.99	127.97
Revenue Growth (YoY)	-98.69%	-75.54%	669.75%	-99.89%	12.51%	-
Cost of Revenue	0	0	0	0	100.49	92.08
Gross Profit	0	0.31	1.25	0.16	43.49	35.9
Selling, General & Admin	37.31	38.04	73.3	60.04	120.21	101.43
Research & Development	29.84	24.05	45.79	47.74	63.4	48.71
Operating Expenses	67.15	62.09	119.08	107.78	183.61	150.14
Operating Income	-67.14	-61.78	-117.84	-107.62	-140.12	-114.24
Interest Expense / Income	9.82	10.99	12.64	9.92	9.2	9.09
Other Expense / Income	47.25	-34.19	117.06	112.53	-0.58	0.53
Pretax Income	-124.21	-38.58	-247.53	-230.06	-148.74	-123.86
Income Tax	-0.09	-0.42	-0.12	-37.53	-0.71	5.25
Net Income	-124.12	-38.16	-247.41	-192.53	-148.04	-129.11
Preferred Dividends	0	0	0	0.27	80.79	0
Net Income Common	-124.12	-38.16	-247.41	-192.8	-228.83	-129.11
Shares Outstanding (Basic)	16	8	4	1	0	0
Shares Outstanding (Diluted)	16	8	4	1	0	0
Shares Change	106.59%	98.51%	249.49%	463.48%	4.84%	-
EPS (Basic)	-7.87	-5.00	-64.33	-175.00	-1171.75	-693.00
EPS (Diluted)	-7.87	-5.00	-64.33	-175.00	-1171.75	-693.00
Free Cash Flow	-48.59	-65.21	-168.34	-169.62	-109.85	-69.96
Free Cash Flow Per Share	-3.08	-8.54	-43.77	-154.12	-562.44	-375.53
Gross Margin	100.00%	100.00%	100.00%	100.00%	30.21%	28.05%
Operating Margin	-1678575.00%	-20256.07%	-9449.64%	-66431.48%	-97.31%	-89.27%
Profit Margin	-3102875.00%	-12510.49%	-19840.58%	-119009.88%	-158.92%	-100.88%
Free Cash Flow Margin	-1214775.00%	-21380.00%	-13499.68%	-104700.62%	-76.29%	-54.67%
EBITDA	-113.84	-26.68	-233.46	-218.71	-134.87	-108.69
EBITDA Margin	-2845875.00%	-8747.54%	-18721.57%	-135004.32%	-93.67%	-84.93%
Depreciation & Amortization	0.56	0.91	1.44	1.44	4.68	6.07
EBIT	-114.39	-27.59	-234.9	-220.15	-139.54	-114.77
EBIT Margin	-2859750.00%	-9044.92%	-18836.81%	-135891.98%	-96.92%	-89.68%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).